Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs F5 Inc (FFIV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs F5 Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while F5 Inc trades at $428.2 (market cap $24.28B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and F5 Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | FFIV | |
|---|---|---|
Market Cap | $39.89B | $24.28B |
Sector | Health | Technology |
52-Week High | $491.22 | $430.39 |
52-Week Low | $278.09 | $223.99 |
Enterprise Value | $38.15B | $23.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
F5 (FFIV) trades at $430.39, showing minimal daily movement with a 0.02% gain. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $3.09B in 2025. Technical indicators signal a bullish trend, with the price above key support levels. Recent strategic moves include AI security platform expansion and acquisitions, positioning the company for continued growth in the cybersecurity sector.
The outlook remains positive with strong earnings momentum and strategic AI investments, though valuation metrics appear elevated. Key risks include competitive pressures and execution challenges in new market segments. Analyst consensus leans cautious with a $397 price target below current levels, suggesting potential near-term consolidation despite long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →
